Slingshot members are tracking this event:
Results of the MEASURE 1 and MEASURE 2 Phase III studies for Novartis' Cosentyx (secukinumab) in ankylosing spondylitis (AS) were published
Slingshot Insights Explained
Dec 23, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Measure, Phase Iii, Cosentyx, Secukinumab, Phase 1, Ankylosing Spondylitis